Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
BLZ-945
CHF 0.00
In stock
SYN-1197-M0011 mgCHF 227.00
SYN-1197-M0055 mgCHF 497.00
SYN-1197-M01010 mgCHF 780.00
SYN-1197-M05050 mgINQ
SYN-1197-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | BLZ945 |
| Product Type | Chemical |
| Properties | |
| Formula | C20H22N4O3S |
| MW | 398.5 |
| CAS | 953769-46-5 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: c-FMS | Kinase Group: PTK | Substrate: Tyrosine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | ADZBMFGQQWPHMJ-RHSMWYFYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
BLZ945 is an orally active, potent and selective colony stimulating factor 1 receptor (CSF-1R) inhibitor, which inhibits CSF-1R activity with an IC(50) of 1nM and is more than 1000-fold selective against its closest receptor tyrosine kinase homologs c-KIT and Platelet-derived Growth Factor Receptor β (PDGFRβ ) as well as more than 200 additional kinases, confirming the selectivity of the compound.
Product References
- Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics: T. Wang, et al.; Int. J. Toxicol. 30, 300 (2011)
- CSF-1R inhibition alters macrophage polarization and blocks glioma progression: S.M. Pyonteck, et al.; Nat. Med. 19, 1264 (2013)
- CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells: D.C. Strachan, et al.; Oncoimmunology 2, e26968 (2013)
- Therapeutically reeducating macrophages to treat GBM: C. Garris & M.J. Pittet; Nat. Med. 19, 1207 (2013)
- Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite: J.A. Krauser, et al.; Xenobiotica 45, 107 (2015)
Related Products
